Patterns of cervical cancer screening among Medicaid beneficiaries
Abstract
Objective
Cervical cancer screening guidelines have evolved over time with the incorporation of human papillomavirus (HPV) testing along with cytology. Current screening guidelines recommend cytological screening every 3 years or HPV testing with or without cytology every 5 years in women age 30–65 years. We examined the use of cervical cancer screening among average‐risk Medicaid beneficiaries.
Design
Retrospective cohort study.
Population
Women age 30–64 years at average risk for cervical cancer who underwent cervical cancer screening with cytology, co‐testing or primary HPV testing from 2013 to 2016.
Methods
The IBM Watson Health Multi‐State Medicaid MarketScan Database was used. Subsequent screening rates within 3 years of the index test were examined.
Main outcome measure
The rate of repeat cervical cancer screening was analysed using a cumulative incidence function.
Results
A total of 265 083 patients were identified. Overall, 43.1% (n = 114 312) had index co‐testing, 55.2% (n = 146 309) had cytology and 1.7% (n = 4462) had primary HPV testing. The cumulative incidence of early, repeat cervical cancer screening was 3.9% at 12 months, 22.7% at 24 months and 33.3% at 36 months. During the period from 12 to 24 months after follow up, 20.9% of women underwent repeat screening while 19.4% underwent repeat screening 24–36 months after the index test. Among women who did not undergo repeat cervical cancer screening, a yearly gynaecological examination was performed in only 16 627 (10.7%) during year 2 and in 11 116 (8.8%) during year 3.
Conclusion
Among average‐risk Medicaid beneficiaries, cervical cancer screening is frequently overused. Women who do not undergo cervical cancer screening are unlikely to undergo routine gynaecological examination.
Tweetable Abstract
Among average‐risk Medicaid beneficiaries, cervical cancer screening is frequently overused.